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BACKGROUND
Information on the use of aspirin to increase healthy independent life span in older 
persons is limited. Whether 5 years of daily low-dose aspirin therapy would extend 
disability-free life in healthy seniors is unclear.
METHODS
From 2010 through 2014, we enrolled community-dwelling persons in Australia and 
the United States who were 70 years of age or older (or ≥65 years of age among 
blacks and Hispanics in the United States) and did not have cardiovascular disease, 
dementia, or physical disability. Participants were randomly assigned to receive 100 mg 
per day of enteric-coated aspirin or placebo orally. The primary end point was a 
composite of death, dementia, or persistent physical disability. Secondary end points 
reported in this article included the individual components of the primary end point 
and major hemorrhage.
RESULTS
A total of 19,114 persons with a median age of 74 years were enrolled, of whom 9525 
were randomly assigned to receive aspirin and 9589 to receive placebo. A total of 56.4% 
of the participants were women, 8.7% were nonwhite, and 11.0% reported previous 
regular aspirin use. The trial was terminated at a median of 4.7 years of follow-up 
after a determination was made that there would be no benefit with continued aspirin 
use with regard to the primary end point. The rate of the composite of death, demen-
tia, or persistent physical disability was 21.5 events per 1000 person-years in the aspi-
rin group and 21.2 per 1000 person-years in the placebo group (hazard ratio, 1.01; 
95% confidence interval [CI], 0.92 to 1.11; P = 0.79). The rate of adherence to the as-
signed intervention was 62.1% in the aspirin group and 64.1% in the placebo group 
in the final year of trial participation. Differences between the aspirin group and the 
placebo group were not substantial with regard to the secondary individual end points 
of death from any cause (12.7 events per 1000 person-years in the aspirin group and 
11.1 events per 1000 person-years in the placebo group), dementia, or persistent 
physical disability. The rate of major hemorrhage was higher in the aspirin group than 
in the placebo group (3.8% vs. 2.8%; hazard ratio, 1.38; 95% CI, 1.18 to 1.62; P<0.001).
CONCLUSIONS
Aspirin use in healthy elderly persons did not prolong disability-free survival over a 
period of 5 years but led to a higher rate of major hemorrhage than placebo. (Fund-
ed by the National Institute on Aging and others; ASPREE ClinicalTrials.gov number, 
NCT01038583.)
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Several large, randomized trials have shown the efficacy of aspirin for the secondary prevention of cardiovascular dis-
ease among persons with a history of coronary 
heart disease or stroke.1-3 The evidence support-
ing a benefit of aspirin therapy in the primary 
prevention of cardiovascular or other chronic 
disease is less conclusive despite favorable trends 
suggesting that aspirin use reduces the incidence 
of cardiovascular events and possibly reduces the 
incidence of cancer and cancer-related mortality, 
particularly from colorectal cancer.4-8 Among 
elderly persons (more so than among younger 
persons), a higher risk of cardiovascular disease 
may increase the benefit of aspirin, but this ben-
efit may be accompanied by an increased risk of 
bleeding.7,9,10 Despite the widespread use of low-
dose aspirin in elderly persons who do not have 
a medical indication for aspirin, there is limited 
evidence that the beneficial effects outweigh the 
risks in this age group.
We conducted the Aspirin in Reducing Events 
in the Elderly (ASPREE) trial, which was a ran-
domized, placebo-controlled trial to investigate 
whether the daily use of aspirin, at a dose of 
100 mg, in healthy, community-dwelling older 
adults would prolong healthy life span, free from 
dementia and persistent physical disability. We 
measured the primary end-point events of death, 
dementia, and persistent physical disability, from 
which we derived the composite primary end 
point of disability-free survival, which was used 
to reflect a healthy life span. This end point was 
chosen to allow an integrated assessment of the 
overall risk–benefit ratio associated with the use 
of aspirin in this population.
Me thods
Trial Design
We conducted this randomized, double-blind, 
placebo-controlled trial at 34 sites in the United 
States and at 16 sites in Australia. The trial 
evaluated the effect of 100 mg of enteric-coated 
aspirin daily, as compared with matching pla-
cebo. Details of the trial design and rationale 
have been published previously.11,12 Bayer Pharma 
(Germany) provided the trial drug (aspirin) and 
placebo but had no other role in the trial. The 
Department of Epidemiology and Preventive Med-
icine at Monash University in Australia coordi-
nated the data collection and was responsible for 
statistical analyses. Coordination of the trial and 
monitoring of sites was conducted by this de-
partment in Australia and by the Berman Center 
for Outcomes and Clinical Research in the United 
States.
The trial was conducted according to the cri-
teria of the International Conference on Har-
monisation for the conduct of clinical trials. The 
institutional review board at each participating 
institution approved the trial, and all the partici-
pants provided written informed consent. The 
authors designed the trial and gathered and ana-
lyzed the data. The first and second authors 
wrote the first draft of the manuscript. All the 
authors vouch for the validity of the trial results, 
the adherence of the trial to the protocol (avail-
able with the full text of this article at NEJM.org), 
and the completeness and accuracy of the re-
porting of adverse events. There was no com-
mercial support for this trial.
Trial Population
Trial participants were community-dwelling men 
and women from Australia and the United States 
who were 70 years of age or older (or ≥65 years 
of age among blacks and Hispanics in the 
United States). Details of the recruitment meth-
ods have been published previously.11 In Australia, 
general practitioners and trial personnel identi-
fied potentially eligible patients, who were then 
sent a letter of invitation to participate. In the 
United States, potential participants were identi-
fied by means of clinic-based mailing lists and 
screening of electronic medical records or by re-
sponses to media advertisements and were sub-
sequently invited to participate by letter.
The eligibility criteria are listed in Table S1 
in the Supplementary Appendix (available at 
NEJM.org) and have been reported previously.11,13 
Persons 70 years of age or older (or ≥65 years of 
age among blacks and Hispanics in the United 
States) were required to be free from any chron-
ic illness that would be likely to limit survival to 
less than 5 years and to be free from document-
ed cardiovascular or cerebrovascular disease. The 
rationale for the younger age selection of blacks 
and Hispanics was based on their higher risk of 
cardiovascular disease or dementia.11,14,15
Key exclusion criteria were a clinical diagno-
sis of dementia, a known high risk of bleeding, 
or a contraindication to aspirin (see the Supple-
mentary Appendix). Potential participants were 
also excluded if they had a score of less than 78 
on the Modified Mini–Mental State Examination 
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(on a scale from 0 to 100, with higher scores 
indicating better function)16 or had substantial 
physical disability, defined as a score of 4 or 5 for 
any one of the six basic activities of daily living 
(bathing, dressing, toileting, transferring, walk-
ing, and feeding) on the Katz Index of Indepen-
dence in Activities of Daily Living (scores for each 
activity range from 1 [no difficulty] to 5 [unable 
to do]; a score of 4 indicates severe difficulty in 
performing the activity).17
Trial Procedures
Participants who met the eligibility criteria at a 
screening visit were enrolled in a 4-week placebo 
run-in phase. Participants who had a rate of 
adherence to pill ingestion, as measured by pill 
count, of 80% or greater during the run-in phase 
were then randomly assigned, in a 1:1 ratio, to 
receive a 100-mg tablet of enteric-coated aspirin 
or matching placebo daily, according to a block-
randomization procedure with stratification ac-
cording to trial center (in the United States) or 
general practice clinic (in Australia) and age (65 
to 79 years or ≥80 years).
Annual in-person visits were supplemented by 
telephone calls every 3 months to encourage 
retention in the trial and telephone calls every 
6 months to collect additional information; de-
tails of the data-collection schedules are pro-
vided in Table S2 in the Supplementary Appendix 
and have been described previously.13 Partici-
pants were considered to be lost to follow-up if, 
in the 12 months before June 12, 2017, trial staff 
had had no personal contact with them, either 
in person or by telephone, and if there was no 
record of attendance of the participant at the 
medical practice.
Event-adjudication committees whose mem-
bers were unaware of the trial-group assignments 
reviewed all the primary and secondary end-
point events and deaths according to established 
definitions (see the Supplementary Appendix). 
Reports on the accumulating data were reviewed 
at regular intervals by the trial sponsor (the Na-
tional Institute on Aging) and by an independent 
data and safety monitoring board, whose mem-
bers had been appointed by the National Insti-
tute on Aging. An international data-manage-
ment committee reviewed site-monitoring reports, 
which included information about adherence to 
the protocol and data quality. The trial partici-
pants, study staff, investigators, and general prac-
titioner associate investigators were unaware of 
the trial-group assignments until the publication 
of this article.
Adherence to the trial intervention was as-
sessed by means of annual tablet counts on re-
turned bottles of aspirin or placebo. The correct 
identity of the tablets (i.e., determination of the 
contents) in the labeled bottles from each batch 
of aspirin or placebo was confirmed by labora-
tory analysis (see the Supplementary Appendix). 
After a nonfatal end-point event, participants 
remained in the trial while taking their assigned 
trial intervention (aspirin or placebo), if they were 
willing.
Trial End Points
The primary end point was disability-free sur-
vival, which was defined as survival free from 
dementia or persistent physical disability. The 
primary composite end point was derived from 
the first occurrences of the end-point events of 
death, dementia, and persistent physical disabil-
ity. The diagnosis of dementia was adjudicated 
according to the criteria of the Diagnostic and 
Statistical Manual of Mental Disorders, fourth edition,18 
and persistent physical disability was considered 
to have occurred when a participant reported 
having an inability to perform or severe diffi-
culty in performing at least one of the six basic 
activities of daily living that had persisted for at 
least 6 months.17 Details regarding the health 
measures and definitions used in this trial are 
listed in Table S2 in the Supplementary Appendix.
The ASPREE trial program had eight prespeci-
fied secondary end points, including the three 
individual components of the primary end point 
— death from any cause, dementia, and persis-
tent physical disability — as reported in this 
article. Other secondary end points included 
fatal and nonfatal cardiovascular disease (includ-
ing stroke), fatal and nonfatal cancer, mild cog-
nitive impairment, depression, and major hem-
orrhage (including clinically significant bleeding 
and hemorrhagic stroke). Further analyses of the 
secondary end points of death, cardiovascular 
disease (including stroke), and major hemorrhage 
are now reported in two accompanying articles 
in the Journal.19,20
Statistical Analysis
Details of the statistical analysis procedures and 
sample-size calculation are provided in the Sup-
plementary Appendix. In brief, we estimated the 
probability of remaining event-free using the 
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Kaplan–Meier method, and its complement, cumu-
lative incidence, was used for plots. In intention-
to-treat analyses, Cox proportional-hazards mod-
els were used to compare the aspirin group with 
the placebo group with regard to time-to-event 
end points and to evaluate effects in subgroups 
with the use of interaction terms.
Subgroups that were specified in the statisti-
cal analysis plan included sex, age (younger than 
the median age vs. the median age or older), 
country of residence (Australia vs. the United 
States), race or ethnic group (white in Australia, 
white in the United States, black, Hispanic, or 
other), body-mass index (the weight in kilograms 
divided by the square of the height in meters; 
<20.0 [underweight], 20.0 to 24.9 [normal weight], 
25.0 to 29.9 [overweight], or ≥30.0 [obese]), pre-
vious regular use of aspirin (yes vs. no), frailty 
category (not frail, prefrail, or frail), personal 
history of cancer (yes vs. no), smoking (never 
smoked, former smoker, or current smoker), and 
the presence of diabetes, hypertension, and dys-
lipidemia at baseline (yes vs. no, for each condi-
tion).11,21 The frailty category was determined on 
the basis of the adapted Fried frailty criteria,21 
which include body weight, strength, exhaustion, 
walking speed, and physical activity (see the 
Supplementary Appendix); the category of pre-
frail included participants who met one or two 
criteria, and the category of frail included those 
who met three or more criteria.
There was no plan for the imputation of 
missing data. Data censoring occurred at the 
latest time point that an end point could have 
been reached and was assumed to be for reasons 
that would not alter the prospect of the partici-
pant having an end point, as compared with 
participants who continued to be followed. There 
was no plan for adjustment for multiple com-
parisons of secondary end points, and only point 
estimates with confidence intervals that were 
unadjusted for multiple comparisons are report-
ed, without P values, except for the safety end 
point of major hemorrhage. For safety analyses, 
a significance level of 0.05 was applied. An in-
terim analysis was planned for when 1893 pri-
mary end-point events had occurred, according 
to a Haybittle–Peto stopping rule.
R esult s
Participants
Recruitment began in March 2010 and ended in 
December 2014, at which time 19,114 partici-
pants had undergone randomization (9525 par-
ticipants to the aspirin group and 9589 to the 
placebo group) (Fig. 1). The demographic and 
clinical characteristics of the participants at base-
line were similar in the two groups (Table 1, and 
Table S3 in the Supplementary Appendix). The 
median age of the participants was 74 years, and 
56.4% of the participants were women.13 A total 
Figure 1. Randomization, Intervention, and Follow-up.
The most common reasons for exclusion from the trial were a history of 
cardiovascular disease, an adherence rate of less than 80% during the 4-week 
placebo run-in period, a Modified Mini–Mental State Examination score of 
less than 78 (on a scale from 0 to 100, with higher scores indicating better 
function), a score of 4 or 5 for any one of the six basic activities of daily living 
(bathing, dressing, toileting, transferring, walking, and feeding) on the Katz 
Index of Independence in Activities of Daily Living (scores for each activity 
range from 1 [no difficulty] to 5 [unable to do]; a score of 4 indicates severe 
difficulty in performing the activity), a low hemoglobin level, high blood 
pressure, or the opinion of the general practitioner or primary care physician. 
Participants could have more than one reason for ineligibility. For participants 
who withdrew from the trial, all the information up to the point of withdrawal 
was included in the analyses. Vital status was obtained in all the participants 
who were lost to follow-up or withdrew consent.
19,114 Underwent randomization
23,163 Were included in the run-in
4049 Were excluded
2453 (60.6%) Were ineligible
1518 (37.5%) Were unwilling
to continue
78 (1.9%) Had other
or unknown reasons
9525 Were assigned to receive aspirin 9589 Were assigned to receive placebo
83,376 Patients were screened
by telephone
139 (1.5%) Were lost to follow-up
118 (1.2%) Withdrew consent
157 (1.6%) Were lost to follow-up
119 (1.2%) Withdrew consent
9525 Were included in the analysis 9589 Were included in the analysis
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of 8.7% of the participants were nonwhite; of 
these, 54.1% were black, 29.3% Hispanic, 9.9% 
Asian, and 6.7% of another race or ethnic 
group.13 A total of 11.0% of the participants 
(7.2% of the participants in Australia and 36.7% 
of those in the United States) reported that they 
Characteristic
Aspirin 
(N = 9525)
Placebo 
(N = 9589)
Age — no. (%)†
65–73 yr 4719 (49.5) 4823 (50.3)
≥74 yr 4806 (50.5) 4766 (49.7)
Female sex — no. (%) 5373 (56.4) 5410 (56.4)
Country — no. (%)
Australia 8322 (87.4) 8381 (87.4)
United States 1203 (12.6) 1208 (12.6)
Race or ethnic group — no. (%)‡
White
Australia 8169 (85.8) 8193 (85.4)
United States 539 (5.7) 549 (5.7)
Black 451 (4.7) 450 (4.7)
Hispanic 240 (2.5) 248 (2.6)
Other 126 (1.3) 149 (1.6)
Body-mass index§ 28.1±4.8 28.1±4.7
Current smoking — no. (%) 352 (3.7) 383 (4.0)
Diabetes mellitus — no. (%)¶ 1027 (10.8) 1030 (10.7)
Hypertension — no. (%)‖ 7065 (74.2) 7148 (74.5)
Dyslipidemia — no. (%)** 6159 (64.7) 6308 (65.8)
Personal history of cancer — no. (%) 1827 (19.2) 1833 (19.1)
Previous regular aspirin use — no. (%)†† 1053 (11.1) 1041 (10.9)
Frailty — no. (%)‡‡
Not frail 5603 (58.8) 5643 (58.8)
Prefrail 3707 (38.9) 3740 (39.0)
Frail 215 (2.3) 206 (2.1)
*  Plus–minus values are means ±SD. There were no significant (P>0.05) differences between the two trial groups; all 
differences were less than 0.25 SD (if means were compared), and odds ratios were between 0.67 and 1.50 (if pro-
portions were compared).
†  The subgroups for age were based on the median age of the participants overall (74 years).
‡  Race and ethnic group were reported by the participants. Other race or ethnic group was defined as any category  
with less than 200 participants overall, which included Aboriginal or Torres Strait Islander (12 participants), Native 
American (6), multiple races or ethnic groups (64), Native Hawaiian or Pacific Islander (11), and those who indicated 
that they were not Hispanic but did not state another race or ethnic group (18).
§  The body-mass index is the weight in kilograms divided by the square of the height in meters.
¶  The presence of diabetes was based on participants’ report of diabetes mellitus or a fasting glucose level of at least 
126 mg per deciliter (≥7 mmol per liter) or receipt of treatment for diabetes.
‖  Hypertension was defined by the receipt of treatment for high blood pressure or a blood pressure of more than 
140/90 mm Hg at trial entry.
**  Dyslipidemia was defined by the receipt of cholesterol-lowering medication or as a serum cholesterol level of at least 
212 mg per deciliter (≥5.5 mmol per liter) in Australia and at least 240 mg per deciliter (≥6.2 mmol per liter) in the 
United States or as a low-density lipoprotein level of more than 160 mg per deciliter (>4.1 mmol per liter).13,21
††  Previous regular aspirin use was defined according to participant-reported regular use of aspirin immediately before 
the first baseline visit, with a 1-month washout period before randomization.
‡‡  Frailty was categorized on the basis of the adapted Fried frailty criteria, which included body weight, strength, exhaus-
tion, walking speed, and physical activity (see the Supplementary Appendix).21 The category of prefrail included partic-
ipants who met one or two criteria, and the category of frail included those who met three or more criteria.
Table 1. Demographic Characteristics and Illness History of the Participants at Randomization, According to Prespecified 
Subgroups and Trial Group.*
The New England Journal of Medicine 
 
 Copyright © 2018 Massachusetts Medical Society. All rights reserved. 
n engl j med nejm.org 6
T h e  n e w  e ngl a nd  j o u r na l  o f  m e dic i n e
had been regular daily users of aspirin before 
participation in the trial.
Starting in February 2015, hazard ratios with 
95% confidence intervals and conditional power 
calculations for the primary end point, without 
P values, were presented every 6 months at closed 
sessions of the data and safety monitoring board. 
In March 2017, the prespecified number of events 
that were required for the interim analysis had 
not been reached, but data to that time showed 
similar rates of the primary end point in the two 
trial groups. This finding made it very unlikely 
that continuation of the trial until its scheduled 
end date of December 31, 2017, would reveal a 
significant treatment effect with aspirin for the 
primary end point. In June 2017, all the trial par-
ticipants were notified of the decision by the Na-
tional Institute on Aging to stop the trial, and they 
were instructed to cease taking the trial interven-
tions (aspirin or placebo) and to return any re-
maining tablets. Participants who had been 
scheduled for trial visits in the remainder of 2017 
were requested to complete a close-out question-
naire to ensure the ascertainment of clinical 
events that had occurred before June 12, 2017. 
Persistent physical disability (of 6 months’ dura-
tion) and dementia end points before this date 
were confirmed by follow-up until December 
2017, in accordance with the protocol.
The median duration of follow-up from ran-
domization was 4.7 years (interquartile range, 
3.6 to 5.7) in each group. More than 90% of the 
due trial visits were completed each year (Table 
S4 in the Supplementary Appendix). By the last 
12 months of the trial, 82.0% of participants 
were still attending annual follow-up visits, 5.5% 
had died, 9.7% were being followed up by regu-
lar telephone contact or through access to clini-
cal and other records, 1.2% had withdrawn, and 
1.6% were lost to follow-up (all the participants 
contributed data to the analyses until the time 
of withdrawal or loss to follow-up) (Table S5 in 
the Supplementary Appendix). Vital status of all 
the participants was assessed after trial closure 
by means of a search of national death records. 
In the final 12 months of the trial, 62.1% of the 
participants in the aspirin group and 64.1% of 
those in the placebo group reported that they 
End Point
Aspirin 
(N = 9525)
Placebo 
(N = 9589)
Hazard Ratio 
(95% CI) P Value
no. of 
participants 
with event
rate per 
1000 person-yr
no. of 
participants 
with event
rate per 
1000 person-yr
Primary end point† 921 21.5 914 21.2 1.01 (0.92–1.11) 0.79
Death from any cause 480 11.2 431 10.0 — —
Dementia 274 6.4 275 6.4 — —
Persistent physical disability 167 3.9 208 4.8 — —
Secondary end points‡
Death from any cause 558 12.7 494 11.1 1.14 (1.01–1.29) —
Dementia 283 6.7 292 6.9 0.98 (0.83–1.15) —
Persistent physical disability 188 4.9 224 5.8 0.85 (0.70–1.03) —
Major hemorrhagic event 361 8.6 265 6.2 1.38 (1.18–1.62) <0.001
Clinically significant bleeding 312 7.4 225 5.3 — —
Hemorrhagic stroke 49 1.2 40 0.9 — —
*  The 95% confidence intervals and P values were not adjusted for multiple comparisons.
†  The primary end point was the first occurrence of any one of the three components (death from any cause, dementia, or persistent physical 
disability).
‡  For the secondary end points, all the participants who had an event at any time during the trial are counted. Other secondary end points 
 included fatal and nonfatal cardiovascular disease, fatal and nonfatal cancer, mild cognitive impairment, and depression. Further results 
 regarding the secondary end points of death, cardiovascular disease (including stroke), and major hemorrhage are reported in two accom-
panying articles in the Journal.19,20
Table 2. Composite Primary End Point, Including the Components, and Secondary End Points of Death, Dementia, Persistent Physical Disability, 
and Major Hemorrhage.*
The New England Journal of Medicine 
 
 Copyright © 2018 Massachusetts Medical Society. All rights reserved. 
n engl j med nejm.org 7
Aspirin and Disability-free Survival in Healthy Elderly
were still taking their assigned intervention 
(Table S6 in the Supplementary Appendix). Details 
regarding adherence to the assigned regimen 
and the use of open-label aspirin are provided in 
Table S7 in the Supplementary Appendix.
Primary End Point
The primary end point of death, dementia, or 
physical disability occurred in 921 participants 
in the aspirin group (21.5 events per 1000 per-
son-years) and in 914 in the placebo group (21.2 
events per 1000 person-years). The between-group 
difference was not significant (hazard ratio, 
1.01; 95% confidence interval [CI], 0.92 to 1.11; 
P = 0.79) (Table 2 and Fig. 2).
No significant interactions of subgroups with 
intervention effects were observed, except for 
frailty (Figs. S1 and S2 in the Supplementary Ap-
pendix). Among participants who had a primary 
end-point event, death was the most common 
first event (in 911 participants [50% of the 
events] at a mean age of 77.5 years), dementia 
was the next most common (in 549 participants 
[30% of the events] at a mean age of 77.7 years), 
and persistent physical disability was the least 
common (in 375 participants [20% of the events] 
at a mean age of 77.6 years) (Table 2).
Secondary End Points
The secondary end point of death from any cause, 
denoting death as the first, second, or third event 
to occur in the primary end point, occurred in 
558 participants in the aspirin group (12.7 events 
per 1000 person-years) and in 494 participants 
in the placebo group (11.1 events per 1000 person-
years) (hazard ratio, 1.14; unadjusted 95% CI, 
1.01 to 1.29). Because there was no adjustment 
for multiple comparisons of secondary end points, 
no inferences can be made regarding differences 
in mortality between the two groups. The rate of 
the secondary end point of all dementia was 6.7 
events per 1000 person-years in the aspirin group 
and 6.9 events per 1000 person-years in the pla-
cebo group (hazard ratio, 0.98; 95% CI, 0.83 to 
1.15) (Table 2 and Fig. 3). The rate of persistent 
physical disability was 4.9 events per 1000 per-
son-years in the aspirin group and 5.8 events per 
1000 person-years in the placebo group (hazard 
ratio, 0.85; 95% CI, 0.70 to 1.03) (Table 2 and 
Fig. 3).
The rates of major hemorrhagic events are 
shown in Table 2. Major hemorrhage occurred in 
3.8% of the participants in the aspirin group, as 
compared with 2.8% of those in the placebo 
group (hazard ratio, 1.38; 95% CI, 1.18 to 1.62; 
P<0.001). Fatal or nonfatal hemorrhagic stroke 
(including subarachnoid hemorrhage) occurred 
in 49 participants (0.5%) in the aspirin group 
and in 40 (0.4%) in the placebo group.
Discussion
In this trial involving community-dwelling older 
adults who were free from known cardiovascular 
disease, dementia, or major physical disability, 
the daily use of 100 mg of enteric-coated aspirin 
did not differ significantly from placebo in influ-
encing the rates of disability-free survival at a 
median of 4.7 years. No significant difference 
was identified regarding the effect of aspirin 
between the participants in the United States 
and those in Australia or across a range of other 
subgroups (prespecified or not prespecified) (Figs. 
S1 and S2 in the Supplementary Appendix). 
White participants comprised 91% of the overall 
trial cohort. Owing to the small number of blacks 
and Hispanics (including participants who were 
younger than 70 years of age) and other non-
Figure 2. Cumulative Incidence of the Primary Composite End Point.
Shown is the cumulative incidence of the primary composite end point 
(death from any cause, dementia, or persistent physical disability) accord-
ing to trial group. First events that counted toward the primary end point 
during the trial included 911 deaths, 549 cases of dementia, and 375 cases 
of persistent physical disability. The graph stops at year 6 because only a 
small number of participants (44 in the aspirin group and 43 in the placebo 
group) reached year 7. The inset shows the same data on an enlarged y axis.
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whites, the applicability of the main findings of 
the ASPREE trial to these subgroups is unclear.
Aspirin has become one of the most popular 
agents used for the primary prevention of car-
diovascular disease, largely on the basis of re-
sults from studies of secondary prevention of 
myocardial infarction and ischemic stroke. Large 
trials investigating primary cardiovascular pre-
vention,22-32 mainly involving participants youn-
ger than those in the ASPREE trial, have not 
shown a consistent effect of aspirin on cardio-
vascular outcomes. In many trials, the use of 
aspirin was accompanied by a higher bleeding 
risk, without any clear indication of overall bene-
fit or harm.23,25-28
Most previous large trials of aspirin have fo-
cused on reducing the incidence of cardiovascu-
lar events as their primary end point. However, 
in this age group, the long-term use of a preven-
tive drug may be justified by a prolongation of 
the time spent in a healthy independent state. 
An end point that reflects this outcome should 
integrate the beneficial effects and the serious 
adverse effects of a preventive agent such as as-
pirin. By reducing platelet aggregation and 
thrombotic obstruction, thereby lessening the 
risk of ischemia in the heart, brain, and other 
organs, aspirin may be expected to reduce the 
incidence of disability from various causes. An 
increased risk of bleeding due to aspirin might 
have an opposite effect because of intracerebral 
and gastrointestinal bleeding and their sequelae. 
In this trial, the primary end point of disability-
free survival was considered to integrate the 
benefits and harms of aspirin and to reflect the 
fundamental purpose for prescribing a preven-
tive agent in an otherwise healthy elderly popu-
lation.
Among the events contributing to the com-
posite primary end point, deaths contributed 
50% of the total, dementia contributed 30%, and 
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Figure 3. Cumulative Incidence of Death, Dementia, 
and Persistent Physical Disability.
Shown are the cumulative incidences of all events of 
death, dementia, and persistent physical disability that 
were observed during the trial. The 95% confidence inter-
vals were not adjusted for multiple comparisons. Insets 
show the same data on an enlarged y axis.
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persistent physical disability 20%. When all the 
events (not just the first event to occur) were 
taken into account, the rates of dementia were 
similar in the two groups and there was no evi-
dence of an effect of aspirin on the rate of per-
sistent physical disability. The difference in the 
rates of death from any cause between the two 
groups could be a chance finding, and previous 
primary prevention trials have not shown signifi-
cantly higher risks of death from any cause with 
aspirin than with placebo or with no treatment. 
However, given the concern about potential harm 
that has been associated with aspirin use in the 
population enrolled in this trial, we investigated 
specific causes of death in separate articles, which 
are now published in the Journal.19,20 As in other 
trials, the incidence of major hemorrhage was 
higher in the aspirin group than in the placebo 
group and amounted to an additional 2.4 serious 
bleeding events per 1000 person-years of exposure.
With regard to the primary end point in this 
trial, the lack of effect of aspirin was consistent 
among all baseline subgroups except for frailty 
(see the Supplementary Appendix). The effect of 
frailty is unclear owing to the inconsistent direc-
tions of the aspirin effect across the three frailty 
categories.
Despite the challenges of maintaining partici-
pation by older persons in a long-term clinical 
trial, a relatively high level of adherence to the 
randomly assigned intervention was maintained 
and was similar to that in other prevention stud-
ies of aspirin.25,28,29 The limitations of our trial 
include the relatively short duration of the inter-
vention, which may be important for detecting an 
effect of aspirin on conditions such as Alzheimer’s 
disease33,34 and cancer,5 which have long laten-
cies between their biologic substrates and clinical 
presentation. The trial results also do not rule 
out a favorable effect of aspirin if its administra-
tion had been commenced at an earlier age or 
continued for a longer period of time.
Interpretation of the trial results should take 
into account the low proportion of participants 
who had been regularly taking low-dose aspirin 
before entering the trial. This trial did not di-
rectly address the question of whether healthy 
older persons who have been using aspirin for 
primary prevention should continue or discon-
tinue its use.
In conclusion, these results of the ASPREE 
trial indicate that, over a median follow-up of 
4.7 years, the use of low-dose aspirin in per-
sons 70 years of age or older who did not have 
cardiovascular disease did not prolong disability-
free survival in a predominantly white population.
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